DK174892B1 - Anvendelse af en kombination af ethinyløstradiol og norethindronacetat til fremstilling af et farmaceutisk præparat til behandling af osteoporosis - Google Patents

Anvendelse af en kombination af ethinyløstradiol og norethindronacetat til fremstilling af et farmaceutisk præparat til behandling af osteoporosis Download PDF

Info

Publication number: DK174892B1
Authority: DK; Denmark
Prior art keywords: approx; osteoporosis; combination; treatment; norethindrone acetate
Prior art date: 1986-02-27

Application number

DK198700999A

Other languages

Danish (da)

English (en)

Other versions

DK99987A (da

DK99987D0 (da

Inventor

Roger Boissoneault

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-02-27

Filing date

1987-02-26

Publication date

2004-01-26

1987-02-26 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1987-02-26 Publication of DK99987D0 publication Critical patent/DK99987D0/da

1987-08-28 Publication of DK99987A publication Critical patent/DK99987A/da

2004-01-26 Application granted granted Critical

2004-01-26 Publication of DK174892B1 publication Critical patent/DK174892B1/da

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
208000001132 Osteoporosis Diseases 0.000 title claims description 7
GEONECATAKDDLT-JDSZYESASA-N (8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol;[(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 GEONECATAKDDLT-JDSZYESASA-N 0.000 title description 3
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 10
229960001652 norethindrone acetate Drugs 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 8
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 7
229960002568 ethinylestradiol Drugs 0.000 claims description 7
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 6
206010030247 Oestrogen deficiency Diseases 0.000 abstract description 2
229940079593 drug Drugs 0.000 abstract description 2
239000003814 drug Substances 0.000 abstract description 2
230000001076 estrogenic effect Effects 0.000 abstract description 2
230000000757 progestagenic effect Effects 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 abstract 2
239000000262 estrogen Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
229940011871 estrogen Drugs 0.000 description 4
238000000034 method Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
239000006186 oral dosage form Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
NAPPWIFDUAHTRY-XYDRQXHOSA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 NAPPWIFDUAHTRY-XYDRQXHOSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000037182 bone density Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
208000029382 endometrium adenocarcinoma Diseases 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
239000002304 perfume Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Dental Preparations (AREA)

DK198700999A 1986-02-27 1987-02-26 Anvendelse af en kombination af ethinyløstradiol og norethindronacetat til fremstilling af et farmaceutisk præparat til behandling af osteoporosis DK174892B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US83426386A	1986-02-27	1986-02-27
US83426386		1986-02-27

Publications (3)

Publication Number	Publication Date
DK99987D0 DK99987D0 (da)	1987-02-26
DK99987A DK99987A (da)	1987-08-28
DK174892B1 true DK174892B1 (da)	2004-01-26

Family

ID=25266516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198700999A DK174892B1 (da)	1986-02-27	1987-02-26	Anvendelse af en kombination af ethinyløstradiol og norethindronacetat til fremstilling af et farmaceutisk præparat til behandling af osteoporosis

Country Status (12)

Country	Link
EP (1)	EP0235090B1 (de)
JP (1)	JP2942560B2 (de)
AT (1)	ATE94392T1 (de)
AU (1)	AU599082B2 (de)
CA (1)	CA1300017C (de)
DE (1)	DE3787386T2 (de)
DK (1)	DK174892B1 (de)
ES (1)	ES2059403T3 (de)
HK (1)	HK182795A (de)
MY (1)	MY101855A (de)
NL (1)	NL300004I1 (de)
ZA (1)	ZA87332B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK174724B1 (da) †	1986-07-15	2003-10-06	Wyeth Corp	Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
HUT52382A (en) *	1988-03-14	1990-07-28	Sandoz Ag	Process for producing pharmaceutical compositions comprising as active ingredient unsubstituted progestin in 19-position and estrogen in the given case
US5059426A (en) *	1989-03-22	1991-10-22	Cygnus Therapeutic Systems	Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) *	1989-03-22	1990-11-27	Cygnus Research Corporation	Skin permeation enhancer compositions
US5053227A (en) *	1989-03-22	1991-10-01	Cygnus Therapeutic Systems	Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
AU640112B2 (en) *	1989-11-03	1993-08-19	Warner-Lambert Company	Estrogen and progestogen containing oral dosage forms
US5591753A (en) *	1994-01-28	1997-01-07	Eli Lilly And Company	Combination treatment for osteoporosis
FR2754179B1 (fr)	1996-10-08	1998-12-24	Theramex	Nouvelle composition hormononale et son utilisation
WO2001030356A1 (fr)	1999-10-25	2001-05-03	Laboratoire Theramex	Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU582540B2 (en) *	1983-08-05	1989-04-06	Pre Jay Holdings Ltd.	A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor

1987
- 1987-01-16 ZA ZA87332A patent/ZA87332B/xx unknown
- 1987-02-12 CA CA000529564A patent/CA1300017C/en not_active Expired - Fee Related
- 1987-02-23 ES ES87810103T patent/ES2059403T3/es not_active Expired - Lifetime
- 1987-02-23 EP EP87810103A patent/EP0235090B1/de not_active Expired - Lifetime
- 1987-02-23 DE DE87810103T patent/DE3787386T2/de not_active Expired - Fee Related
- 1987-02-23 AT AT87810103T patent/ATE94392T1/de not_active IP Right Cessation
- 1987-02-23 AU AU69130/87A patent/AU599082B2/en not_active Ceased
- 1987-02-26 JP JP62041570A patent/JP2942560B2/ja not_active Expired - Lifetime
- 1987-02-26 DK DK198700999A patent/DK174892B1/da not_active IP Right Cessation
- 1987-09-22 MY MYPI87001878A patent/MY101855A/en unknown
1995
- 1995-11-30 HK HK182795A patent/HK182795A/en not_active IP Right Cessation
2000
- 2000-02-09 NL NL300004C patent/NL300004I1/nl unknown

Also Published As

Publication number	Publication date
ZA87332B (en)	1987-08-26
AU599082B2 (en)	1990-07-12
HK182795A (en)	1995-12-08
DK99987A (da)	1987-08-28
DE3787386T2 (de)	1994-05-05
JP2942560B2 (ja)	1999-08-30
ATE94392T1 (de)	1993-10-15
MY101855A (en)	1992-01-31
ES2059403T3 (es)	1994-11-16
AU6913087A (en)	1987-09-03
CA1300017C (en)	1992-05-05
EP0235090B1 (de)	1993-09-15
EP0235090A1 (de)	1987-09-02
JPS62205024A (ja)	1987-09-09
DK99987D0 (da)	1987-02-26
DE3787386D1 (de)	1993-10-21
NL300004I1 (nl)	2000-04-03

Legal Events

Date	Code	Title	Description
2006-09-25	PBP	Patent lapsed	Country of ref document: DK

Publication	Publication Date	Title
EP0402950B1 (de)	1993-09-01	Behandlung von Störungen in der Postmenopause
US4425339A (en)	1984-01-10	Treatment of menopausal symptoms
KR100369206B1 (ko)	2003-04-16	에스트로겐및게스타겐함유피임용조성물
DK174071B1 (da)	2002-05-21	Kontraceptivt præparat i form af en pakning omfattende enhedsdoser
US5510341A (en)	1996-04-23	Ovulation-inhibiting preparation for hormonal contraception
AU678150B2 (en)	1997-05-22	Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses
KR100352571B1 (ko)	2003-01-06	배합호르몬피임약제
IE61236B1 (en)	1994-10-19	Combination dosage form for pre-menopausal women
JPH04290828A (ja)	1992-10-15	低エストロゲン経口避妊薬
PL186339B1 (pl)	2003-12-31	Wieloskładnikowy hormonalny preparat antykoncepcyjny na bazie naturalnego estrogenu
DK174892B1 (da)	2004-01-26	Anvendelse af en kombination af ethinyløstradiol og norethindronacetat til fremstilling af et farmaceutisk præparat til behandling af osteoporosis
JPH11503440A (ja)	1999-03-26	ホルモン避妊用医薬の複合調剤
JP2002509524A (ja)	2002-03-26	エストロゲン化合物とプロゲステロン様化合物よりなるホルモン組成物
AU747710B2 (en)	2002-05-23	Progestogen-antiprogestogen regimens
EP0322020A1 (de)	1989-06-28	Pharmazeutische Dosierungseinheit zur Behandlung von klimakterischen Beschwerden und Osteoporosis
AU640112B2 (en)	1993-08-19	Estrogen and progestogen containing oral dosage forms
CA2134961C (en)	2007-05-15	Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses
MXPA00004610A (en)	2001-05-07	Progestogen-antiprogestogen regimens